The cancer cells in the liver are the same type of cells that started in the bowel. Secondary cancers happen when cancer cells break off the primary cancer and move through the body. This can happen by cancer cells passing through the blood or the lymphatic system. The lymphatic system is a network of tubes and glands that filters body fluid and fights infection. The cancer cells can travel through the blood and lymphatic systems to other parts of the body. They can then grow and develop into another cancer in that part of the body.
Cancer can spread to anywhere in the body but there are places that it is more likely to spread to depending on where your cancer started.
So for example bowel cancers are most likely to spread to the liver and lungs and cancers that start in the lungs is more likely to spread to the brain and bones. Treatment will depend on where your cancer started. This is because the primary and secondary cancer cells are the same and will respond to the same types of treatment.
Treatment might include one or more types. You should talk to your doctor to find out how the treatment will work.
Once a cancer has spread it can be more difficult to cure. The aim of treatment may be to control the growth of the cancer and any symptoms you have for as long as possible or sometimes the aim might be to get rid of the cancer completely.
For more information about secondary cancer go to cruk. For more information about your cancer type go to cruk. Remember that aches and pains are common and may be a muscle strain or an everyday ache. Tell your doctor if you have a new pain. Andersen, T. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? Vignery, A. Macrophage fusion: are somatic and cancer cells possible partners? Trends Cell Biol.
Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB variants. Abe, M. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Gonzalez-Suarez, E. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. This paper highlights the bone-independent role of RANKL that may provide new targeted approaches for breast cancer therapy.
Clarke, N. Morphometric evidence for bone resorption and replacement in prostate cancer. Roudier, M. Histopathological assessment of prostate cancer bone osteoblastic metastases. Koeneman, K. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 , — Dudley, A. Calcification of multipotent prostate tumor endothelium. Cancer Cell 14 , — Odero-Marah, V. Brubaker, K.
L, Brown, L. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.
Prostate 56 , 13—22 Leong, D. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Akech, J.
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29 , — RUNX2, traditionally known to be osteoblast specific, was found to be highly expressed in metastatic prostate cancer cells and associated with tumour growth in bone.
This highlights the osteomimicry of tumour cells that metastasize to bone and provides a new target to consider for therapeutic development. Chackal-Roy, M. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. Gleave, M. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cooper, C. Stromal factors involved in prostate carcinoma metastasis to bone.
Cancer 97 , — De Palma, M. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Acta , — Stockmann, C. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Silva, R. Integrins: the keys to unlocking angiogenesis. Prantl, L. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70 , — Klopp, A. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.
Studeny, M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Bianco, P. Gene Ther. Yang, L. Bingle, L. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
Dirkx, A. Gabrilovich, D. The terminology issue for myeloid-derived suppressor cells. Vaira, S. Melani, C. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 44 , — Dunn, G. Interferons, immunity and cancer immunoediting. Takayanagi, H.
Osteoimmunology and the effects of the immune system on bone. Sato, K. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. Gay, L. Contribution of platelets to tumour metastasis. Cancer 11 , — Boucharaba, A.
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. This paper shows that lysophosphatidic acid derived from activated platelets can promote tumour growth and osteolysis in a mouse model of bone metastases. APT, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. PubMed Central Google Scholar. Beeton, C. Osteoclast formation and bone resorption are inhibited by megakaryocytes.
Bone 39 , — Chollet, M. Studies from normal and grey platelets. Lemieux, J. Bernasconi, S. Effects of granulocyte-monocyte colony-stimulating factor GM-CSF on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Cancer 60 , — Zaslavsky, A. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Fidler, I. Luzzi, K. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.
Damiano, J. Cell adhesion mediated drug resistance CAM-DR : role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 , — Morgan, T. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Diel, I. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Watson, M. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Zhang, X. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16 , 67—78 Rack, B.
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Neoplasia 12 , — Rogers, M. New insights into the molecular mechanisms of action of bisphosphonates. Gnant, M. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. Stopeck, A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Jensen, A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Breast Cancer 10 , — Rucci, N. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med. Desgrosellier, J. Integrins in cancer: biological implications and therapeutic opportunities.
Cancer 10 , 9—22 Cancer 46 , — Balooch, G. Mohammad, K. Edwards, J. Buijs, J. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Doctors aren't sure what causes some cancers to spread.
And it's not clear why some cancers travel to the bones rather than to other common sites for metastasis, such as the liver. Virtually any type of cancer can spread to the bones, but the cancers most likely to cause bone metastasis include:. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
This content does not have an English version. This content does not have an Arabic version. Overview Bone metastasis occurs when cancer cells spread from their original site to a bone. Request an Appointment at Mayo Clinic. Share on: Facebook Twitter.
Survival rates for people with bone metastases vary greatly by cancer type and stage. Your general health condition and the type of treatment you received for the primary cancer are additional factors. Discuss your particular situation with your doctor. Remember that survival rates are averages gathered from large numbers of people. Also, survival data may reflect statistics from a period before the most recent treatment advances. A large-scale study of the 10 most common cancers with bone metastasis found:.
Here are some typical figures from a study of common cancers and bone metastasis:. Your treatment plan will depend on:. Specific drugs that target bones are an important part of therapy and a developing research area.
A breast cancer study reported a lower risk of bone complications for people who started treatment within 6 months of a bone metastasis diagnosis. As we learn more about the mechanisms of how cancer cells invade and disrupt bones, scientists develop new ways of targeting and slowing these cancer cells.
Note that most cancer treatments have side effects. Discuss these with your doctors and evaluate the benefits versus risks for your treatment. Ask your doctors about new developments in the field that may help you. Drug development for cancer is a fast-moving research area. The medical literature has articles on new possibilities under development and testing. For example, the use of nanoparticles has the promise of enhancing both current drugs and new drugs under development.
Nanoparticles can be used to deliver drugs to the metastasis site with fewer side effects. You may be eligible for a clinical trial. Clinical trials test out new drugs, experiment with new treatments, and compare the outcome of existing treatment combinations.
0コメント